Abstract 1795P
Background
In the global ARCHES trial (NCT02677896), ENZA + ADT improved overall survival and radiographic progression-free survival (rPFS) vs PBO + ADT in pts with mHSPC. The China ARCHES trial evaluated the efficacy and safety of ENZA + ADT vs PBO + ADT in Chinese pts with mHSPC.
Methods
Chinese men with mHSPC (positive bone scan or CT scan) were randomized 2:1 to ENZA (160 mg/day) + ADT or PBO + ADT, stratified by disease volume and prior docetaxel therapy. Treatment continued until intolerability or confirmed radiographic progression. The primary endpoint was time to prostate-specific antigen (PSA) progression (TTPP; PSA progression defined as ≥25% increase and absolute increase of ≥2 ng/mL above the nadir, confirmed after ≥3 weeks), based on central laboratory test. Selected secondary endpoints included rPFS, time to castration resistance (TTCR), PSA undetectable (<0.2 ng/mL) rate in patients with detectable PSA at baseline, and safety. We report the results of a prespecified interim analysis (63 TTPP events accrued).
Results
At data cut-off (November 18, 2022), 180 pts (ENZA + ADT, n=120; PBO + ADT, n=60) had been randomized from 27 centers in China (median age, 68.5 years). Baseline characteristics were balanced between treatment arms. Median treatment duration with ENZA + ADT vs PBO + ADT was 25.66 vs 15.11 months. Based on 63 centrally confirmed PSA progressions (ENZA + ADT, 23; PBO + ADT, 40), ENZA + ADT significantly reduced the risk of PSA progression by 87% vs PBO + ADT (Table). rPFS, TTCR, and PSA undetectable rate were among the secondary endpoints improved with ENZA + ADT vs PBO + ADT. Safety outcomes in pts from China were consistent with those in the global ARCHES population. Table: 1795P
Endpoint | ENZA + ADT N=120 | PBO + ADT N=60 | Hazard ratioa (95% CI) | p value |
TTPPb (95% CI)c | NR (NR, NR) | 9.2 (6.54, 17.48) | 0.13 (0.076, 0.222) | <0.0001d |
rPFSb (95% CI)c | NR (28.25, NR) | 19.4 (13.63, NR) | 0.33 (0.196, 0.556) | <0.0001d,e |
TTCRb (95% CI)c | NR (31.18, NR) | 8.3 (6.41, 14.69) | 0.172 (0.107, 0.276) | <0.0001d,e |
PSA undetectable, % (95% CI)f | 76.3 (67.4, 83.8) | 22.8 (12.7, 35.8) | <0.0001e,g |
aCox proportional hazards modelh bMedian months: Kaplan-Meier method cBrookmeyer and Crowley method dLog-rank testh eNominal p value fClopper-Pearson method based on exact binomial distribution gCochran-Mantel-Haenszel score testh hStratified model/test CI=confidence interval; N=no. of randomized pts; NR=not reached.
Conclusions
Efficacy and safety results in China ARCHES were generally consistent with those in the global ARCHES trial.
Clinical trial identification
Editorial acknowledgement
Medical writing and editorial assistance were provided by Marietou Daou, MSc, and Jane Beck, MA, from Complete HealthVizion, IPG Health Medical Communications, funded by the study sponsors.
Legal entity responsible for the study
Astellas Pharma Inc.; Pfizer Inc.
Funding
This study was funded by Astellas Pharma Inc. and Pfizer Inc., the co-developers of enzalutamide.
Disclosure
F. Zhou, Z. Gongqian, H. Guo, Z. Hu, D. He, D. Zhang, Y. Li, H. Kadeerbai, Y. Liu, D. Ye: Non-Financial Interests, Institutional, Other, Study funding and support for Medical Writing/editing: Astellas; Non-Financial Interests, Institutional, Other, Medical writing/editing support: Complete HealthVizion. X. Zhang, Z. He: Non-Financial Interests, Institutional, Writing Engagement: Astellas Pharma Inc.
Resources from the same session
1783P - PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14